Inventor · disambiguated record
Simona Volpi
Also filed as: VOLPI SIMONA
15 granted patents·9 pending applications·75 citations·filing 2005–2019
92Inventor score
Top patents by PatentIndex Score
24 records- 0191US9328387B2Antipsychotic treatment based on SNP genotypeLAVEDAN CHRISTIAN·Filed 2008·Granted May 3, 2016·16 cites·12 claims
- 0289US9458507B1Antipsychotic treatment based on SNP genotypeVANDA PHARMACEUTICALS INC·Filed 2016·Granted Oct 4, 2016·7 cites·12 claims
- 0389US9080214B2Genetic markers for efficacy of iloperidone in the treatment of psychotic symptomsLAVEDAN CHRISTIAN·Filed 2008·Granted Jul 14, 2015·8 cites·13 claims
- 0485US9074254B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2008·Granted Jul 7, 2015·6 cites·6 claims
- 0585US8652776B2Prediction of QT prolongation based on SNP genotypeLAVEDAN CHRISTIAN·Filed 2008·Granted Feb 18, 2014·12 cites·8 claims
- 0684US9074255B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2010·Granted Jul 7, 2015·6 cites·10 claims
- 0784US9074256B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2010·Granted Jul 7, 2015·6 cites·10 claims
- 0884US9072742B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2010·Granted Jul 7, 2015·6 cites·10 claims
- 0981US10563261B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2017·Granted Feb 18, 2020·2 cites·10 claims
- 1079US10570453B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2018·Granted Feb 25, 2020·1 cites·5 claims
- 1179US9057104B2Antipsychotic treatment based on DRD2 or ANKK1 SNP genotypeLAVEDAN CHRISTIAN·Filed 2010·Granted Jun 16, 2015·1 cites·14 claims
- 1278US9408839B2Antipsychotic treatment based on DRD2 or ANKK1 SNP genotypeVANDA PHARMACEUTICALS INC·Filed 2015·Granted Aug 9, 2016·1 cites·14 claims
- 1377US9243295B2Antipsychotic treatment based on DRD2 or ANKK1 SNP genotypeVANDA PHARMACEUTICALS INC·Filed 2015·Granted Jan 26, 2016·1 cites·14 claims
- 1476US10570452B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·1 cites·10 claims
- 1576US10563260B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2017·Granted Feb 18, 2020·1 cites·10 claims
- 1664US2010063093A1Methods for the administration of iloperidoneWOLFGANG CURT·Filed 2008·Application pending·0 cites
- 1763US2019360047A1Methods for the administration of iloperidoneVANDA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1860US2014039008A1Methods for the administration of iloperidoneVANDA PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1952US2016053324A1Methods for the administration of iloperidoneVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2049US2015259747A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2147US2015225794A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2247US2015225795A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2347US2015225793A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2442US2008033053A1Cross-Reference To Related ApplicationsWOLFGANG CURT D·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →